



Technology Advisory Committee B Interests Register Lu vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more therapies [ID3840] Publication Date: 15/11/2023


Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Peter Wheatley Price	TAC B Committee Member	Indirect – Financial Interest	Takeda manufacture leuprorelin which is one a number of products used to treat prostate cancer in the hormone sensitive stage		06/09/23		It was agreed that these declarations would not prevent Peter Wheatley Price from participating in the meeting.
Professor Nicholas Latimer	TAC B Committee Member	Indirect financial interest	He was paid to give Novartis staff a training session on survival analysis. This was not product or appraisal specific and was about methods. Novartis are the manufacturer (October 2021)		30/08/22		It was agreed that these declarations would not prevent Professor Latimer from being participating in the meeting.
Professor Nicholas Latimer	TAC B Committee Member	Non-financial professional and personal interest	He is also a member of the ScHARR team for a consultancy project involving the adjustment for treatment switching observed in the NETTER-1 trial, comparing lutathera to best supportive care alone in patients with advanced, progressive, somatostatin-receptorpositive midgut neuroendocrine tumours.		30/08/22		It was agreed that these declarations would not prevent Professor Latimer from being participating in the meeting.



Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
			Lutathera is made by Advanced Accelerator Applications (AAA) Ltd, a Novartis company. Novartis are the manufacturer.				
Professor David McAllister	TAC B Committee Member	Non-financial professional and personal interest	Part of the research he conducts uses data provided by sponsors (or competitors) provided via public trial repositories. Access is managed via an independent steering committee and neither I nor my organisation receive any funds from the trial companies for the work done.		24/08/22 09/01/23		It was agreed that these declarations would not prevent Professor McAllister from participating in the meeting.
Professor Amit Bahl	Clinical expert	Various indirect financial interests	They sat on advisory boards for Advisory boards for Sanofi, Astellas, BMS, Janssen, Pfizer, Bayer, EUSA, AAA (Novartis). Professor Bahl has also sat on advisory boards for Accord, alongside having received sponsorship for meetings and educational lectures.		30/05/22 12/01/22		It was agreed that these declarations would not prevent Professor Bahl from providing expert advice to the committee.
Dr Amarnath Challapalli	Clinical expert	Indirect financial interest	He has received speaker fees and honoraria from Janssen, Sanofi, Bayer and Astellas. Dr Challapalli was also part of		23/11/21 12/01/23		It was agreed that these declarations would not prevent Dr Challapalli



Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
			ERG review panel for Lu- PSMA and was responsible for starting the EMES programme for Lu-PSMA at the University Hospitals Bristol NHS Foundation Trust.				from providing expert advice to the committee.
Professor Sabina Dizdarevic	Clinical expert	Indirect financial interests	Having been a member of an advisory board for Novartis, alongside receiving educational platform consultancy agreement for PSMA treatment, and receiving speaker fees from GE and Bayer		15/09/22 12/03/23		It was agreed that these declarations would not prevent Professor Dizdarevic from providing expert advice to the committee.
Professor Sabina Dizdarevic	Clinical expert	Indirect financial interest	Has been a BNSM Council member and Research Lead Chair of the ICSCNM, RCR/RC		16/11/22 12/03/23		It was agreed that these declarations would not prevent Professor Dizdarevic from providing expert advice to the committee.
Dr Veline L'Esperance	TAC B Committee Member	Indirect financial	Her employer, Operose Health, received a grant from Novartis to undertake a Quality Improvement Project on lipid optimisation within primary care. Dr Veline L'Esperance stated that the grant was not related to this topic's disease area nor did		03/01/23		It was agreed that her declaration would not prevent Dr Veline L'Esperance from participating in discussions on this appraisal.



Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
			she personally benefit financially from this grant.				
Dr Stephen Allen	Patient Expert	indirect financial interest	Tackle Prostate Cancer receive funding from a large number of pharmaceutical companies.		12/01/23		It was agreed that his declaration would not prevent Dr Stephen Allen from providing expert advice to the committee.